Azithromycin (Zedbac®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32014001446
English
Authors' recommendations:
Azithromycin (Zedbac®) 500 mg powder for solution for infusion is recommended as an option for restricted use within NHS Wales. Azithromycin (Zedbac®) 500 mg powder for solution for infusion should be restricted for use within NHS Wales for the treatment of community-acquired pneumonia (CAP) due to susceptible microorganisms, in adult patients where initial intravenous therapy is required. Azithromycin (Zedbac®) 500 mg powder for solution for infusion is not recommended for use within NHS Wales for the treatment of pelvic inflammatory disease (PID) due to susceptible microorganisms, in patients where initial intravenous therapy is required.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/2476
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Pneumonia
- Pelvic Inflammatory Disease
- Community-Acquired Infections
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.